Follow The Filings

MRNA Moderna

Health Care, filed as MODERNA INC (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 2 managers in 2026 Q2

  • 1 Owner
  • Max 0.2%
  • $640K
  • 1 reduce

In 2026 Q3 Murphy Pohlad trimmed Moderna.

Who owns this now

Largest portfolio weights among holders, up to 0.2% (Murphy Pohlad, Murphy Pohlad Asset Management). Not free-float ownership.

  1. Murphy Pohlad Reduce 0.22%

Who owns MRNA

Sorted by value, long equity only, as of 2026 Q3.

History
Murphy Pohlad, Murphy Pohlad Asset Management 0.22% Reduce −13.1% 3,324 $640K History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by MRNA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All MRNA insider trades
  • None no insider bought on the open market
  • $1.1M sold by 1 insider outside a trading plan
  • $80.2M sold by 4 insiders under 10b5-1 plans
  1. Stephen Hoge President
    Planned sale
    $17M 78,369 shares at $217.10 4.6% of stake
    Traded Oct 14–15 Filed Oct 16
    ↗
  2. Stephen Hoge President
    Planned sale
    $11.7M 80,575 shares at $145.10 4.9% of stake
    Traded Sep 14–15 Filed Sep 16
    ↗
  3. James M Mock CFO
    Planned sale
    $4.7M 34,836 shares at $134.49 37% of stake
    Traded Sep 10 Filed Sep 14
    ↗
  4. Shannon Thyme Klinger Chief Legal Officer
    Planned sale
    $486K 3,471 shares at $139.95 4.5% of stake
    Traded Sep 1 Filed Sep 3
    ↗
  5. Stephane Bancel CEO
    Planned sale
    $28.7M 499,246 shares at $57.52 7.5% of stake
    Traded Aug 5 Filed Aug 7
    ↗
  6. Stephen Hoge President
    Planned sale
    $3.6M 53,336 shares at $67.60 3.5% of stake
    Traded Jul 15 Filed Jul 16
    ↗
  7. Stephen Hoge President
    Planned sale
    $2.7M 53,336 shares at $51.37 3.5% of stake
    Traded Jun 15 Filed Jun 17
    ↗
  8. Shannon Thyme Klinger Chief Legal Officer
    Planned sale
    $174K 3,471 shares at $50.00 4.9% of stake
    Traded Jun 4 Filed Jun 8
    ↗
  9. Noubar Afeyan Director
    Sale
    $434K 9,263 shares at $46.84 70% of stake
    Traded May 21 Filed May 22
    ↗
  10. Stephen Hoge President
    Planned sale
    $2.6M 53,336 shares at $48.40 3.5% of stake
    Traded May 15 Filed May 18
    ↗
  11. Shannon Thyme Klinger Chief Legal Officer
    Planned sale
    $726K 13,885 shares at $52.29 19% of stake
    Traded Mar 2 Filed Mar 3
    ↗
  12. Stephen Hoge President
    Planned sale
    $7.8M 160,009 shares at $48.84 9.9% of stake
    Traded Feb 23 Filed Feb 25
    ↗
  13. Noubar Afeyan Director
    Sale
    $703K 23,853 shares at $29.49 86% of stake
    Traded Dec 11, 2025 Filed Dec 15, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 76 option exercises, 53 share withholdings for taxes, 4 stock grants, and 2 sales to cover taxes.

Congress

4 members of Congress traded MRNA in the last three years: 2 buys and 5 sales. 1 member listed it in 2025 annual reports.

All Congress trades
  1. Maria Elvira Salazar R-FL-27 Partial sale $1K–$15K Sep 24 filed Oct 7
  2. Maria Elvira Salazar R-FL-27 Buy $1K–$15K Aug 19 filed Sep 9
  3. Maria Elvira Salazar R-FL-27 Partial sale $1K–$15K Aug 19 filed Sep 9
  4. Robert P. Bresnahan, Jr. R-PA-8 Sell $1K–$15K Apr 8, 2025 filed May 8, 2025
  5. Robert P. Bresnahan, Jr. R-PA-8 Buy $1K–$15K Feb 25, 2025 filed Mar 27, 2025
  6. Julie Johnson D-TX-32Joint Sell $1K–$15K Jan 15, 2025 filed Feb 12, 2025

SEC filings

Recent issuer filings from EDGAR, 9 shown.

Filed Form Detail Links
8-K 5.02,7.01,9.01 Filing Doc
8-K 1.01,2.03,3.02,8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 5.03,5.07,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 12 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $6.85B $3.24B $1.94B
Gross profit * $2.16B $1.77B $1.08B
Gross margin * 31.5% 54.8% 55.3%
Net income -$4.71B -$3.56B -$2.82B
Net margin * -68.8% -110.0% -145.2%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $10.32B $8.1B $6.54B
Total non-current assets * $8.1B $6.04B $5.79B
Total assets $18.43B $14.14B $12.34B
Total current liabilities $3.02B $2.21B $1.99B
Total non-current liabilities * $1.56B $1.04B $1.7B
Total equity $13.85B $10.9B $8.65B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$3.12B -$3B -$1.87B
Cash from investing $4.21B $1.95B $1.95B
Cash from financing -$1.38B $0.056B $0.593B
Net change in cash -$289M -$999M $668M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.